AU2005267579A1 - 1 (indole-6-carbonyl-D-phenylglycinyl) -4- (1-methylpiperidin-4-yl) piperazine D-tartrate - Google Patents
1 (indole-6-carbonyl-D-phenylglycinyl) -4- (1-methylpiperidin-4-yl) piperazine D-tartrate Download PDFInfo
- Publication number
- AU2005267579A1 AU2005267579A1 AU2005267579A AU2005267579A AU2005267579A1 AU 2005267579 A1 AU2005267579 A1 AU 2005267579A1 AU 2005267579 A AU2005267579 A AU 2005267579A AU 2005267579 A AU2005267579 A AU 2005267579A AU 2005267579 A1 AU2005267579 A1 AU 2005267579A1
- Authority
- AU
- Australia
- Prior art keywords
- tartrate
- piperazine
- carbonyl
- indole
- phenylglycinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- VYNKVNDKAOGAAQ-RUZDIDTESA-N n-[(1r)-2-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-2-oxo-1-phenylethyl]-1h-indole-6-carboxamide Chemical compound C1CN(C)CCC1N1CCN(C(=O)[C@H](NC(=O)C=2C=C3NC=CC3=CC=2)C=2C=CC=CC=2)CC1 VYNKVNDKAOGAAQ-RUZDIDTESA-N 0.000 title claims description 12
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 title claims description 11
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical class OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 claims description 15
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 11
- 208000007536 Thrombosis Diseases 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000013078 crystal Substances 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 102000035195 Peptidases Human genes 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000004365 Protease Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- 108010074860 Factor Xa Proteins 0.000 description 4
- 108010022999 Serine Proteases Proteins 0.000 description 4
- 102000012479 Serine Proteases Human genes 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 229960001270 d- tartaric acid Drugs 0.000 description 4
- 150000004683 dihydrates Chemical class 0.000 description 4
- 229960004592 isopropanol Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- DHWVDLFBAPQUOT-OTWIGTIJSA-N (2S,3S)-2,3-dihydroxybutanedioic acid dihydrate Chemical compound O.O.O[C@@H]([C@H](O)C(O)=O)C(O)=O DHWVDLFBAPQUOT-OTWIGTIJSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OHUMKYGINIODOY-UHFFFAOYSA-N 1-(1-methylpiperidin-4-yl)piperazine Chemical compound C1CN(C)CCC1N1CCNCC1 OHUMKYGINIODOY-UHFFFAOYSA-N 0.000 description 2
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000005388 cross polarization Methods 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- -1 piperazine D-tartaric acid salt Chemical class 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 229960000103 thrombolytic agent Drugs 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 101710140722 Cocoonase Proteins 0.000 description 1
- 102000016917 Complement C1 Human genes 0.000 description 1
- 108010028774 Complement C1 Proteins 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- ZGUNAGUHMKGQNY-SSDOTTSWSA-N D-alpha-phenylglycine Chemical compound OC(=O)[C@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-SSDOTTSWSA-N 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 108010054265 Factor VIIa Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 101710136618 Inter-alpha-trypsin inhibitor Proteins 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 238000005004 MAS NMR spectroscopy Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 101710180012 Protease 7 Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 238000005384 cross polarization magic-angle spinning Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940012414 factor viia Drugs 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- YUWFEBAXEOLKSG-UHFFFAOYSA-N hexamethylbenzene Chemical compound CC1=C(C)C(C)=C(C)C(C)=C1C YUWFEBAXEOLKSG-UHFFFAOYSA-N 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 108010059841 serine carboxypeptidase Proteins 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000001622 two pulse phase modulation pulse sequence Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58359904P | 2004-06-30 | 2004-06-30 | |
| US60/583,599 | 2004-06-30 | ||
| PCT/US2005/020490 WO2006011955A1 (en) | 2004-06-30 | 2005-06-13 | 1 (indole-6-carbonyl-d-phenylglycinyl) -4- (1-methylpiperidin-4-yl) piperazine d-tartrate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2005267579A1 true AU2005267579A1 (en) | 2006-02-02 |
Family
ID=35276192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005267579A Abandoned AU2005267579A1 (en) | 2004-06-30 | 2005-06-13 | 1 (indole-6-carbonyl-D-phenylglycinyl) -4- (1-methylpiperidin-4-yl) piperazine D-tartrate |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20070249623A1 (enExample) |
| EP (1) | EP1763521A1 (enExample) |
| JP (1) | JP2008505075A (enExample) |
| CN (1) | CN1984903A (enExample) |
| AR (1) | AR049659A1 (enExample) |
| AU (1) | AU2005267579A1 (enExample) |
| BR (1) | BRPI0512245A (enExample) |
| CA (1) | CA2570634A1 (enExample) |
| EA (1) | EA010307B1 (enExample) |
| EC (1) | ECSP067105A (enExample) |
| IL (1) | IL179903A0 (enExample) |
| MA (1) | MA28842B1 (enExample) |
| MX (1) | MXPA06015112A (enExample) |
| NO (1) | NO20070486L (enExample) |
| PE (1) | PE20060480A1 (enExample) |
| SV (1) | SV2006002156A (enExample) |
| TW (1) | TW200603806A (enExample) |
| WO (1) | WO2006011955A1 (enExample) |
| ZA (1) | ZA200610091B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0616574D0 (en) * | 2006-08-21 | 2006-09-27 | Glaxo Group Ltd | Compounds |
| CN107365304A (zh) * | 2017-08-01 | 2017-11-21 | 齐宜涛 | 一种治疗心血管疾病的化合物及制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA51676C2 (uk) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
| GB9821058D0 (en) * | 1998-09-28 | 1998-11-18 | Univ Cardiff | Chemical compound |
| DE60022742D1 (de) * | 1999-03-15 | 2006-02-02 | Novo Nordisk As | Salz des (2r,3r,4r)-3,4-dihydroxy-2-hydroxmethylpyrrolidins |
| CA2375920A1 (en) * | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Compounds |
| US6448293B1 (en) * | 2000-03-31 | 2002-09-10 | Pfizer Inc. | Diphenyl ether compounds useful in therapy |
| GB0030304D0 (en) * | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0019228D0 (en) * | 2000-08-04 | 2000-09-27 | Smithkline Beecham Plc | Novel pharmaceutical |
| HRP20030910B1 (hr) * | 2001-05-14 | 2011-11-30 | Pfizer Products Inc. | Tartaratne soli 5,8,14-triazatetraciklo {10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>}-heksadeka-2(11), 3,5,7,9-pentaena i pripadajućih farmaceutskih spojeva |
| TWI257389B (en) * | 2001-06-12 | 2006-07-01 | Lilly Co Eli | Pharmaceutical compound |
-
2005
- 2005-06-13 CN CNA2005800214090A patent/CN1984903A/zh active Pending
- 2005-06-13 WO PCT/US2005/020490 patent/WO2006011955A1/en not_active Ceased
- 2005-06-13 BR BRPI0512245-7A patent/BRPI0512245A/pt not_active IP Right Cessation
- 2005-06-13 AU AU2005267579A patent/AU2005267579A1/en not_active Abandoned
- 2005-06-13 CA CA002570634A patent/CA2570634A1/en not_active Abandoned
- 2005-06-13 EP EP05760368A patent/EP1763521A1/en not_active Withdrawn
- 2005-06-13 JP JP2007519246A patent/JP2008505075A/ja active Pending
- 2005-06-13 US US11/570,686 patent/US20070249623A1/en not_active Abandoned
- 2005-06-13 MX MXPA06015112A patent/MXPA06015112A/es not_active Application Discontinuation
- 2005-06-13 EA EA200700186A patent/EA010307B1/ru not_active IP Right Cessation
- 2005-06-17 TW TW094120115A patent/TW200603806A/zh unknown
- 2005-06-27 PE PE2005000741A patent/PE20060480A1/es not_active Application Discontinuation
- 2005-06-29 SV SV2005002156A patent/SV2006002156A/es not_active Application Discontinuation
- 2005-06-29 AR ARP050102705A patent/AR049659A1/es unknown
-
2006
- 2006-12-01 ZA ZA200610091A patent/ZA200610091B/en unknown
- 2006-12-07 IL IL179903A patent/IL179903A0/en unknown
- 2006-12-20 EC EC2006007105A patent/ECSP067105A/es unknown
-
2007
- 2007-01-25 NO NO20070486A patent/NO20070486L/no not_active Application Discontinuation
- 2007-01-29 MA MA29641A patent/MA28842B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200610091B (en) | 2008-02-27 |
| US20070249623A1 (en) | 2007-10-25 |
| AR049659A1 (es) | 2006-08-23 |
| JP2008505075A (ja) | 2008-02-21 |
| BRPI0512245A (pt) | 2008-02-19 |
| IL179903A0 (en) | 2007-05-15 |
| WO2006011955A1 (en) | 2006-02-02 |
| CA2570634A1 (en) | 2006-02-02 |
| EA010307B1 (ru) | 2008-08-29 |
| TW200603806A (en) | 2006-02-01 |
| MXPA06015112A (es) | 2007-02-08 |
| EA200700186A1 (ru) | 2007-06-29 |
| CN1984903A (zh) | 2007-06-20 |
| SV2006002156A (es) | 2006-02-15 |
| MA28842B1 (fr) | 2007-09-03 |
| PE20060480A1 (es) | 2006-07-13 |
| EP1763521A1 (en) | 2007-03-21 |
| ECSP067105A (es) | 2007-01-26 |
| NO20070486L (no) | 2007-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI443088B (zh) | Ｘａ因子抑制劑之新穎醫藥鹽及多晶型 | |
| KR20010014165A (ko) | 오메프라졸 나트륨염 | |
| CA2888100A1 (en) | Crystalline forms of a factor xia inhibitor | |
| CN115916780A (zh) | (9r,13s)-13-{4-[5-氯-2-(4-氯-1h-1,2,3-三唑-1-基)苯基]-6-氧代-1,6-二氢嘧啶-1-基}-3-(二氟甲基)-9-甲基-3,4,7,15-四氮杂三环[12.3.1.02,6]十八-1(18),2(6),4,14,16-五烯-8-酮的晶型 | |
| CN115463133B (zh) | 一种药物组合物、制剂及其制备方法和应用 | |
| EP1397348B1 (en) | Factor xa inhibitor | |
| US20070249623A1 (en) | 1-(Indole-6-Carbonyl-D-Phenylglycinyl)-4-(1-Methylpiperidin-4-Yl)Piperazine D-Tartrate | |
| KR101852226B1 (ko) | 오타믹사반의 벤조산염 | |
| KR100849242B1 (ko) | 1(인돌-6-카르보닐-ｄ-페닐글리시닐)-4-(1-메틸피페리딘-4-일) 피페라진 ｄ-타르트레이트 | |
| US20080051388A1 (en) | Novel Compounds That Inhibit Factor Xa Activity | |
| JP6357100B2 (ja) | ６−（ピペリジン−４−イルオキシ）−２ｈ−イソキノリン−１−オン塩酸塩の結晶性溶媒和物 | |
| US7388096B2 (en) | Crystalline forms of a factor Xa inhibitor | |
| TWI880627B (zh) | 一種二肽類化合物的鹽、其製備方法和用途 | |
| CZ20011216A3 (cs) | Benzamidové deriváty | |
| CA2589886A1 (en) | Crystalline forms of a factor xa inhibitor | |
| HK40082657B (en) | Pharmaceutical composition, formulation thereof, preparation method therefor and use thereof | |
| EP2805705B1 (en) | Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid | |
| HK40082657A (en) | Pharmaceutical composition, formulation thereof, preparation method therefor and use thereof | |
| MX2008005143A (en) | Pharmaceutical salts and polymorphs of n- (5-chl0r0-2-pyridinyl) -2- [ [4- [ (dimethylamino) iminomethyl]benzoyl]amino]-5-meth oxy-benzamide, a factor xa inhibitor | |
| HK1189584B (en) | Benzoic acid salt of otamixaban |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |